logo Ibionextlogo Ibionext
  • HOME
  • ABOUT US
  • STRATEGY
  • TEAM
  • OUR COMPANIES
  • NEWS & MEDIA
  • CONTACT
  • Français
Twitter
LinkedIn

Year: 2020

Home 2020

TILAK HEALTHCARE winner of the Prix Galien 2020 e-Health category

December 18, 2020Press releasesIbionext

Pour OdySight, le jeu mobile de télésurveillance médicale des maladies chroniques ophtalmologiques Paris, France – 18 décembre 2020 – Tilak Healthcare, société pionnière spécialisée dans le développement de jeux mobiles avec modules médicaux destinés au suivi de patients atteints de…

Chronolife chooses Mulliez-Flory to manufacture their connected textiles on an industrial scale

December 17, 2020Press releasesIbionext

Paris, December 17th, 2020 – Chronolife, a French artificial intelligence company specializing in digital health, announced today that they have chosen the Cholet-headquartered Mulliez-Flory textile family to provide 100% integrated solutions (creation, manufacturing, distribution, recycling) for the industrial manufacturing of…

Tilak Healthcare inks a new partnership agreement in ophtalmology with Novartis to expand internationally (To promote OdySight®, an innovative vision monitoring technology)

December 8, 2020Press releasesIbionext

Paris, December 8, 2020 – Tilak Healthcare, a digital therapeutics pioneer specializing in the development of mobile medical application games used as monitoring and rehabilitation tools for chronic diseases, is proud to announce a framework agreement with Novartis Pharma AG…

Chronolife’s Nexkin Biometric T-Shirt Enables Continuous Real-Time Health Monitoring

December 1, 2020NewsIbionext

Chronolife was back at CES 2020 with its biometric smart T-Shirt Nexkin launched in November 2019, a consumer version of Chronolife’s medical solution that is expected to launch as a remote health monitoring product in 2020, with FDA and CE…

GrAI Matter Labs raises $14M for edge AI inferencing

November 30, 2020NewsIbionext

GrAI Matter Labs, a Paris-based startup developing a neuromorphic computing architecture for edge AI inferencing, raised $14 million in a venture round led by iBionext. GrAI Matter Labs’ existing investors also participated in the round, as well as new investor…

Medical monitoring: Chronolife partners with be-ys to optimize remote care of patients with chronic disease

November 24, 2020Press releasesIbionext

Paris, (France) November 24th, 2020 – Chronolife, an artificial intelligence company specialized in digital health, and be-ys, expert in health data management and security, have both decided to combine their skills in order to offer healthcare professionals a turnkey service…

BrainEver Receives FDA Orphan Drug Designation for BREN-02, (human recombinant Engrailed 1) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

November 23, 2020Press releasesIbionext

Paris, France, November 23th, 2020 – BrainEver, a biotechnology company dedicated to the research and development of innovative therapies for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation…

GrAI Matter Labs Raises $14M to Bring Fastest AI per Watt to Every Device on the Edge

November 23, 2020Press releasesIbionext

NOVEMBER 23, 2020 PARIS- GrAI Matter Labs, a pioneer of brain inspired ultra-low latency computing, today announced its latest financing round of $14 million. The round was led by iBionext, joined by all existing investors and newly welcomed Bpifrance through…

BFM Business – Bernard Gilly (GrAI Matter Labs): the Franco-American start-up raises $14 million with its AI inspired by the human brain

November 23, 2020NewsIbionext

Interview de Bernard Gilly sur BFM Business : https://www.bfmtv.com/economie/replay-emissions/tech-and-co/bernard-gilly-gr-ai-matter-labs-la-start-up-franco-americaine-leve-14-millions-de-dollars-grace-a-son-ia-inspiree-du-cerveau-humain-23-11_VN-202011230336.html

BrainEver Receives FDA Orphan Drug Designation for BREN-02, (human recombinant Engrailed 1) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

November 23, 2020Press releasesIbionext

Paris, France, November 23th, 2020 – BrainEver, a biotechnology company dedicated to the research and development of innovative therapies for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation…

Posts navigation

1 2 3 4 >

SEARCH

ARCHIVES

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

CATEGORIES

  • Events (3)
  • News (78)
  • Press releases (84)

LATEST NEWS

  • Chronolife and Infiniwell join forces to deliver end-to-end remote health monitoring services March 22, 2023
  • Prophesee named in Best of MWC 2023 Awards by Android Authority February 28, 2023
  • Prophesee Announces Collaboration with Qualcomm to Optimize Neuromorphic Vision Technologies For the Next Generation of Smartphones, Unlocking a New Image Quality Paradigm for Photography and Video February 27, 2023
  • Prophesee named to La French Tech 120 February 20, 2023
  • Chronolife announces a strategic partnership with SAMI Advanced Electronics in Saudi Arabia February 14, 2023

CONTACT US

74, rue du Faubourg Saint-Antoine 75012 Paris
+33 1 76 21 47 50
contact@ibionext.com

LEGAL NOTICES

  • Cookies Policy
  • Privacy Policy
  • Terms of use
© 2023 iBionext. All rights reserved